Targeting brain metastases in advanced NSCLC: The emerging impact of ADCs
touchPANEL DISCUSSION for touchONCOLOGY and touchRESPIRATORY
Listen to leading experts discuss the role of antibody–drug conjugates (ADCs) in NSCLC with brain metastases, including the latest clinical trial evidence, practical approaches to patient selection and treatment sequencing alongside local CNS therapies, and the evolving pipeline of investigational ADCs.
The expert(s)
Dr Lyudmila Bazhenova, Moore’s Cancer Center, San Diego, CA, USA
Dr Elvire Pons-Tostivint, Nantes Université, Centre Hospitalier Universitaire Nantes, France
Dr Julia Rotow, Dana-Farber Cancer Institute, Boston, MA, USA…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.